Buy Sugistran 12.5mg in UAE | Ernest Oncology – Oncology Meds Supplier

Sunixar 12.5 mg Capsule: Precision Targeted Therapy for Oncology Care

Are you searching for a reliable Sunixar 12.5 mg capsule exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced oncology medications. We cater to major international markets, including the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa, providing high-quality pharmaceutical solutions with professional B2B support.

Product Overview: What is Sunixar 12.5 mg?

Sunixar 12.5 mg is an oral targeted therapy medication containing Sunitinib Malate. It belongs to the class of Tyrosine Kinase Inhibitors (TKIs) and is widely utilized in modern oncology to treat specific types of tumors that are resistant to traditional chemotherapy.

Primary Therapeutic Indications:

Sunixar 12.5 mg is clinically indicated for:

• Renal Cell Carcinoma (RCC): Advanced or metastatic kidney cancer.

• Gastrointestinal Stromal Tumors (GIST): Rare cancers of the digestive tract, especially after other treatments (like imatinib) have failed or cannot be tolerated.

• Pancreatic Neuroendocrine Tumors (pNET): Progressive, well-differentiated tumors of the hormone-producing cells in the pancreas.

• Adjuvant Treatment of RCC: For patients at high risk of recurrent kidney cancer following surgery (nephrectomy).

Mechanism of Action: How Sunixar Works:

Sunixar works by inhibiting multiple receptor tyrosine kinases (RTKs) that are overactive in cancer cells. These receptors are responsible for signaling the cell to grow and divide.

1. Inhibition of Tumor Growth: It blocks receptors like PDGFR and KIT, which are essential for cancer cell survival and proliferation.

2. Anti-Angiogenesis: It targets VEGFR (Vascular Endothelial Growth Factor Receptors), preventing the formation of new blood vessels that the tumor needs to receive oxygen and nutrients to expand.

3. Targeted Attack: By disrupting these cellular pathways, Sunixar helps slow down or stop the spread of cancer while potentially sparing more healthy cells than conventional chemo.

Dosage and Administration Guidelines:

• Cycle for RCC/GIST: Often prescribed as 50 mg (four 12.5 mg capsules) daily for 4 weeks, followed by a 2-week rest period (the 4/2 schedule).

• Continuous Dosing for pNET: Typically a continuous daily dose (often 37.5 mg) without a rest period.

• Method: Take the capsule whole with water. It can be taken with or without food.

• Critical Warning: Patients must avoid grapefruit and grapefruit juice during treatment, as they can significantly increase the drug's concentration in the blood, leading to toxicity.

Common Side Effects & Monitoring:

While effective, patients may experience:

• Fatigue, nausea, or diarrhea.

• Hand-Foot Syndrome: Redness, swelling, or pain on the palms and soles.

• High blood pressure (hypertension).

• Changes in taste or skin/hair discoloration.

• Monitoring: Regular checks of thyroid function, liver enzymes (LFTs), and blood pressure are essential during therapy.

Why Source Sunixar 12.5 mg from Ernest Oncology?

• Quality Assurance: We supply authentic medications manufactured under strict quality controls and GMP compliance.

• Bulk Availability: Consistent stock of 12.5 mg, 25 mg, and 50 mg strengths for clinical and hospital requirements.

• Global Export Expertise: Seamless shipping and customs handling for the UK, London, USA, Abu Dhabi, Australia, and South Africa.

• Competitive B2B Pricing: Optimized rates for international distributors, oncology centers, and healthcare providers.